Alrex is a drug owned by Bausch And Lomb Inc. It is protected by 5 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 25, 2014. Details of Alrex's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5747061 (Pediatric) | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) |
Expired
|
|
US5540930 (Pediatric) | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) |
Expired
|
| US5747061 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(11 years ago) |
Expired
|
| US5540930 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(11 years ago) |
Expired
|
|
US4996335 (Pediatric) | Soft steroids having anti-inflammatory activity |
Sep, 2012
(12 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Alrex is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Alrex's family patents as well as insights into ongoing legal events on those patents.
Alrex's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Alrex's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 25, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Alrex Generic API suppliers:
Loteprednol Etabonate is the generic name for the brand Alrex. 5 different companies have already filed for the generic of Alrex, with Sentiss having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Alrex's generic
Alternative Brands for Alrex
Alrex which is used for treating seasonal allergic conjunctivitis., has several other brand drugs using the same active ingredient (Loteprednol Etabonate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Alcon Labs Inc |
| ||
| Bausch And Lomb |
| ||
| Bausch And Lomb Inc |
| ||
| Pharmos |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Loteprednol Etabonate, Alrex's active ingredient. Check the complete list of approved generic manufacturers for Alrex
About Alrex
Alrex is a drug owned by Bausch And Lomb Inc. It is used for treating seasonal allergic conjunctivitis. Alrex uses Loteprednol Etabonate as an active ingredient. Alrex was launched by Bausch And Lomb in 1998.
Approval Date:
Alrex was approved by FDA for market use on 09 March, 1998.
Active Ingredient:
Alrex uses Loteprednol Etabonate as the active ingredient. Check out other Drugs and Companies using Loteprednol Etabonate ingredient
Treatment:
Alrex is used for treating seasonal allergic conjunctivitis.
Dosage:
Alrex is available in suspension/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.2% | SUSPENSION/DROPS | Prescription | OPHTHALMIC |